Menière’s disease: combined pharmacotherapy with betahistine and the MAO-B inhibitor selegiline—an observational study

[1]  D. Rujescu,et al.  Retraction Note to: Menière’s disease: combined pharmacotherapy with betahistine and the MAO-B inhibitor selegiline—an observational study , 2018, Journal of Neurology.

[2]  M. Burton,et al.  Betahistine for Menière's disease or syndrome. , 2018, Cochrane Database of Systematic Reviews.

[3]  L. Vécsei,et al.  Monoamine Oxidase B Inhibitors in Parkinson's Disease. , 2017, CNS & neurological disorders drug targets.

[4]  E. Ferrary,et al.  Meniett device in meniere disease: Randomized, double‐blind, placebo‐controlled multicenter trial , 2017, The Laryngoscope.

[5]  A. H. Hassan,et al.  Transbuccal delivery of betahistine dihydrochloride from mucoadhesive tablets with a unidirectional drug flow: in vitro, ex vivo and in vivo evaluation , 2016, Drug design, development and therapy.

[6]  P. Cayé-Thomasen,et al.  Expression of histamine receptors in the human endolymphatic sac: the molecular rationale for betahistine use in Menieres disease , 2016, European Archives of Oto-Rhino-Laryngology.

[7]  A. Schilder,et al.  Betahistine for symptoms of vertigo. , 2016, The Cochrane database of systematic reviews.

[8]  M. Strupp,et al.  Efficacy and safety of betahistine treatment in patients with Meniere’s disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial) , 2016, British Medical Journal.

[9]  F. Sallee,et al.  Safety, tolerability and pharmacokinetics of 2‐pyridylacetic acid, a major metabolite of betahistine, in a phase 1 dose escalation study in subjects with ADHD , 2015, Biopharmaceutics & drug disposition.

[10]  M. Strupp,et al.  Diagnostic criteria for Menière's disease. , 2015, Journal of vestibular research : equilibrium & orientation.

[11]  M. Strupp,et al.  Histaminergic H3-Heteroreceptors as a Potential Mediator of Betahistine-Induced Increase in Cochlear Blood Flow , 2015, Audiology and Neurotology.

[12]  W. Grolman,et al.  Intratympanic gentamicin treatment for Ménière’s disease: a randomized, double-blind, placebo-controlled trial on dose efficacy - results of a prematurely ended study , 2014, Trials.

[13]  Rania M. Hathout,et al.  Transdermal delivery of betahistine hydrochloride using microemulsions: physical characterization, biophysical assessment, confocal imaging and permeation studies. , 2013, Colloids and surfaces. B, Biointerfaces.

[14]  M. J. Derebery,et al.  Oral Steroid Treatment for Hearing Improvement in Ménière’s Disease and Endolymphatic Hydrops , 2012, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

[15]  M. Strupp,et al.  Betahistine Exerts a Dose-Dependent Effect on Cochlear Stria Vascularis Blood Flow in Guinea Pigs In Vivo , 2012, PloS one.

[16]  B. Westerberg,et al.  Intratympanic steroids for Ménière's disease or syndrome. , 2011, The Cochrane database of systematic reviews.

[17]  K. Jahn,et al.  High-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Menière’s disease: a case series , 2011, European Archives of Oto-Rhino-Laryngology.

[18]  M. Paparella,et al.  Meniere's disease , 2008, The Lancet.

[19]  Adrian James,et al.  Menière's disease. , 2007, BMJ clinical evidence.

[20]  A. Burgess,et al.  Diuretics for Ménière's disease or syndrome. , 2006, The Cochrane database of systematic reviews.

[21]  A. Pfleiderer,et al.  A national survey amongst UK otolaryngologists regarding the treatment of Ménière’s disease , 2005, The Journal of Laryngology & Otology.

[22]  D. Zhong,et al.  LC-MS-MS analysis of 2-pyridylacetic acid, a major metabolite of betahistine: application to a pharmacokinetic study in healthy volunteers , 2003, Xenobiotica; the fate of foreign compounds in biological systems.

[23]  K. Sotaniemi,et al.  Selegiline as initial treatment in de novo parkinsonian patients , 1992, Neurology.

[24]  A. J. Lees,et al.  Deprenyl administration in man: A selective monoamine oxidase B inhibitor without the ‘cheese effect’ , 1978, Psychopharmacology.

[25]  A. Tobia,et al.  The metabolism of betahistine in the rat. , 1974, Drug metabolism and disposition: the biological fate of chemicals.

[26]  M. Lacour.  Betahistine treatment in managing vertigo and improving vestibular compensation: clarification. , 2013, Journal of vestibular research : equilibrium & orientation.

[27]  Anthony E. Lang,et al.  Effect of deprenyl on the progression of disability in early Parkinson's disease. , 1989, The New England journal of medicine.

[28]  S. Shapiro.  The surgery of Meniere's disease. , 1971, Eye, ear, nose & throat monthly.